Dr Abdul Mannan: Clonal Haematopoiesis – More Common, More Complex
Dr Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, posted on LinkedIn:
“Clonal Haematopoiesis: More Commoon. More Complex. More Relevant Than We Realised.
Today I shared an updated infographic on Clonal Haematopoiesis – a topic that has quietly moved from academic curiosity to something every clinician should have on their radar.
What struck me most while putting this together is how far beyond cancer this story goes.
For years, we framed CHIP and CCUS as “pre-leukaemic”. The problem is… that’s only half the picture.
These tiny clones behave like slow-burning fires.
They sit in the marrow, send out inflammatory signals, and nudge the immune system into a persistent “low-grade storm”. The result?
Higher rates of ischaemic heart disease, stroke, and heart failure, particularly with mutations like TET2, DNMT3A, JAK2 V617F.
And in the real world, that’s often where the danger lies.
The infographic breaks it down clearly:
- CHIP – mutation present, blood counts normal
- CCUS – mutation + sustained cytopenias
- High-risk CCUS – where leukaemic transformation risk climbs
- VEXAS – the perfect reminder that a “clonal process” doesn’t always behave like a cancer
It also highlights a simple monitoring approach that doesn’t overwhelm patients or clinics:
- CHIP → annual CBC
- CCUS → every 3–6 months
- High-risk patterns → consider marrow assessment and closer follow-up
As haematologists, we’re used to dealing with rapid, dramatic conditions.
Clonal haematopoiesis is the opposite.
Quiet. Slow. Easy to miss.
Until it isn’t.
If you’re teaching trainees, reviewing cardiology referrals, or running a general haematology clinic, this is a space worth understanding.
I’ll keep sharing more simplified, practical resources like this – to make the science accessible not just for exam preparation, but for real clinical decision-making.
Happy to discuss cases, interpretations, and grey areas.
The dialogue around this is just beginning.”
Follow the latest with Hemostasis Today.
-
Dec 6, 2025, 18:02ASH25 Day 1: Don’t Miss The Highlights
-
Dec 6, 2025, 15:44Atul Gupta on Where The Healthcare Innovation is Headed
-
Dec 6, 2025, 15:22Nathan White on How Inflammation Contributes to Coagulopathy After Trauma
-
Dec 6, 2025, 15:02Anas Younes on AstraZeneca’s Aims in Blood Cancer to Be Presented at ASH25
-
Dec 6, 2025, 14:08David Alderman: ASH25 is Live
-
Dec 6, 2025, 13:53Isabelle Mahé Presents The Proposals from INNOVTE CAT Working Group
-
Dec 6, 2025, 11:50Steve Tuplin on Roche’s Mission at ASH25
-
Dec 6, 2025, 11:13Khaled Musallam on The Lancet Haematology Podcast: Your ASH25 Roadmap
-
Dec 6, 2025, 06:34Akshat Jain: It was Wonderful Hosting and Meeting Industry Leaders on Their Visit Down to Southern California